>

Publications

2026

Vermudez SAD, Freitas GA, Smith M, Gogliotti RG, Niswender CM, Profiling metabotropic glutamate receptor 7 expression in Rett syndrome: consequences for pharmacotherapy Neuroscience. 2026 Jan 30; 598 9-18
Henderson SH, Ringuette AE, Whomble DL, Capstick RA, Richardson AE, Maurer MA, Billard NB, Lei X, Wilkinson JC, Kethanapalli SH, Cho HP, Rodriguez AL, Niswender CM, Peng W, Rook JM, Chang S, Blobaum AL, Boutaud O, Felts AS, Conn PJ, Lindsley CW, Temple KJ, Discovery of 7-(Pyridin-3-yl)thieno[3,2-]pyridine-5-carboxamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 ACS chemical neuroscience. 2026 Jan 25; 17 (3) 610-623
Gregro AR, Park C, Long MF, Baker LA, Bollinger KA, Ringuette AE, Peng L, Luscombe VB, Billard NB, Rodriguez AL, Niswender CM, Peng W, Dickerson JW, Rook JM, O'Neill J, Chang S, Boonen HCM, Jensen T, Thomsen MS, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ, Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust Efficacy ACS chemical neuroscience. 2026 Jan 25; 17 (3) 649-665

2025

Reed CW, Kalbfleisch JF, Turkett JA, Trombley TA, Spearing PK, Haymer DH, Quitalig M, Dickerson JW, Foster DJ, Blobaum AL, Boutaud O, Cho HP, Niswender CM, Rook JM, Priepke H, Sommer H, Scheuerer S, Ursu D, Conn PJ, Melancon BJ, Lindsley CW, Further Optimization of the mGlu PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685 ACS chemical neuroscience. 2025 Feb 05; 16 (4) 745-752
Engers JL, Li J, Han C, Long MF, Gregro AR, Presley CC, Dickerson JW, Peng W, Cho HP, Rodriguez AL, Xiang Z, Boutaud O, O'Carroll C, Dey PM, Burstein ES, Niswender CM, Rook JM, Conn PJ, Engers DW, Lindsley CW, Application of Deuterium in an M Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422 ACS chemical neuroscience. 2025 Mar 25; 16 (8) 1582-1591
Crocker KE, Henderson SH, Capstick RA, Whomble DL, Bender AM, Felts AS, Han C, Engers JL, Billard NB, Maurer MA, Cho HP, Rodriguez AL, Niswender CM, O'Neill J, Watson KJ, Chang S, Blobaum AL, Boutaud O, Peng W, Rook JM, Conn PJ, Lindsley CW, Temple KJ, Discovery of Thieno[3,2-]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 ACS medicinal chemistry letters. 2025 Apr 22; 16 (5) 865-874
Engers JL, Bollinger SR, Gregro AR, Capstick RA, Spearing PK, Long MF, Tarr JC, Watson KJ, Chang S, Luscombe VB, Rodriguez AL, Cho HP, Qi A, Niswender CM, Bubser M, Gould RW, Robb WH, Byun N, Gore J, Jones CK, Thomsen MS, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ, Discovery of Pre-Clinical Candidate /: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy ACS chemical neuroscience. 2025 May 26; 16 (11) 2141-2162
Rodriguez AL, Qi A, Han A, Kling HE, Quitalig MC, Bender AM, Barbaro L, Whomble D, Lindsley CW, Niswender CM, Characterization of Novel and Known Activators of Cannabinoid Receptor Subtype 2 Reveals Mixed Pharmacology That Differentiates Mycophenolate Mofetil and GW-842,166X from MDA7 International journal of molecular sciences. 2025 May 21; 26 (10)
Dong HW, Weiss K, Dickerson JW, Meadows MJ, Zagol-Ikapitte I, Boutaud O, Rook JM, Neul JL, Niswender CM, Potentiation of group III metabotropic glutamate receptors positively affects neurophysiological features in a mouse model of Rett syndrome The Journal of pharmacology and experimental therapeutics. 2025 May 08; 392 (6) 103602
Freitas GA, Weiss K, Bavadekar V, Vermudez SAD, Fisher NM, Buch A, Dogra S, Xiang Z, Gogliotti RG, Niswender CM, Overexpression of mGlu in Mice: Implications for Neurodevelopmental Disorders Molecular neurobiology. 2025 Jul 10; 62 (11) 14015-14031
Bungard JD, Spearing P, Nishio Y, Rathnayake U, Presley CC, Chang S, Kling HE, Thompson AD, Cho HP, Peng L, Rodriguez AL, Niswender CM, Boutaud O, Kramlinger V, Jones CK, Conn PJ, Engers JL, Engers DW, Lindsley CW, Han C, Discovery of a Novel sp‑Rich M Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping ACS medicinal chemistry letters. 2025 Jun 17; 16 (7) 1231-1238
Lei X, Xiang Z, Rodriguez AL, Wilson ML, Niswender CM, Profiling the Impact of mGlu/Elfn1 Protein Interactions on the Pharmacology of mGlu Allosteric Modulators ACS chemical neuroscience. 2025 Jul 21; 16 (15) 2872-2886

2024

Parent HH, Niswender CM, Therapeutic Potential for Metabotropic Glutamate Receptor 7 Modulators in Cognitive Disorders Molecular pharmacology. 2024 Apr 17; 105 (5) 348-358
Ferranti AS, Luessen DJ, Niswender CM, Novel pharmacological targets for GABAergic dysfunction in ADHD Neuropharmacology. 2024 Mar 08; 249 109897
Dennys CN, Vermudez SAD, Deacon RJM, Sierra-Delgado JA, Rich K, Zhang X, Buch A, Weiss K, Moxley Y, Rajpal H, Espinoza FD, Powers S, Ávila AS, Gogliotti RG, Cogram P, Niswender CM, Meyer KC, MeCP2 gene therapy ameliorates disease phenotype in mouse model for Pitt Hopkins syndrome Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2024 Jun 14; 21 (5) e00376
Dong HW, Weiss K, Baugh K, Meadows MJ, Niswender CM, Neul JL, Potentiation of the muscarinic acetylcholine receptor 1 modulates neurophysiological features in a mouse model of Rett syndrome Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2024 Jun 15; 21 (4) e00384
Li J, Orsi DL, Engers JL, Long MF, Capstick RA, Maurer MA, Presley CC, Vinson PN, Rodriguez AL, Han A, Cho HP, Chang S, Jackson M, Bubser M, Blobaum AL, Boutaud O, Nader MA, Niswender CM, Conn PJ, Jones CK, Lindsley CW, Han C, Development of VU6036864: A Triazolopyridine-Based High-Quality Antagonist Tool Compound of the M Muscarinic Acetylcholine Receptor Journal of medicinal chemistry. 2024 Aug 06; 67 (16) 14394-14413
Capstick RA, Bollinger SR, Engers JL, Long MF, Chang S, Luscombe VB, Rodriguez AL, Niswender CM, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ, Discovery of VU6008677: A Structurally Distinct Tricyclic M Positive Allosteric Modulator with Improved CYP450 Profile ACS medicinal chemistry letters. 2024 Jul 03; 15 (8) 1358-1366
Engers JL, Bollinger KA, Capstick RA, Long MF, Bender AM, Dickerson JW, Peng W, Presley CC, Cho HP, Rodriguez AL, Niswender CM, Moran SP, Xiang Z, Blobaum AL, Boutaud O, Rook JM, Engers DW, Conn PJ, Lindsley CW, Discovery of VU6007496: Challenges in the Development of an M Positive Allosteric Modulator Backup Candidate ACS chemical neuroscience. 2024 Aug 28; 15 (18) 3421-3433
Engers JL, Baker LA, Chang S, Luscombe VB, Rodriguez AL, Niswender CM, Cho HP, Bubser M, Gray AT, Jones CK, Peng W, Rook JM, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ, Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) ACS chemical neuroscience. 2024 Sep 24; 15 (20) 3744-54
Lin X, Provasi D, Niswender CM, Asher WB, Javitch JA, Elucidating the molecular logic of a metabotropic glutamate receptor heterodimer Nature communications. 2024 Oct 03; 15 (1) 8552
Qi A, Han X, Quitalig M, Wu J, Christov PP, Jeon K, Jana S, Kim K, Engers DW, Lindsley CW, Rodriguez AL, Niswender CM, The cannabinoid CB receptor positive allosteric modulator EC21a exhibits complicated pharmacology Journal of receptor and signal transduction research. 2024 Nov 22; 44 (4) 151-159
Reed CW, Kalbfleisch JF, Turkett JA, Trombley TA, Nastase AF, Spearing PK, Haymer DH, Sarwar MM, Quitalig M, Dickerson JW, Blobaum AL, Boutaud O, Voehringer P, Schuelert N, Cho HP, Niswender CM, Rook JM, Priepke H, Ursu D, Conn PJ, Melancon BJ, Lindsley CW, Discovery of VU6024578/BI02982816: An mGlu Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models Journal of medicinal chemistry. 2024 Dec 12; 67 (24) 22291-22312
Childress ES, Capstick RA, Crocker KE, Ledyard ML, Bender AM, Maurer MA, Billard NB, Cho HP, Rodriguez AL, Niswender CM, Peng W, Rook JM, Chang S, Blobaum AL, Boutaud O, Thompson Gray A, Jones CK, Conn PJ, Felts AS, Lindsley CW, Temple KJ, Discovery of 4-(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 ACS medicinal chemistry letters. 2024 Nov 18; 15 (12) 2210-2219
Poslunsey MS, Wood MR, Han C, Stauffer SR, Panarese JD, Melancon BJ, Engers JL, Dickerson JW, Peng W, Noetzel MJ, Cho HP, Rodriguez AL, Hopkins CR, Morrison R, Crouch RD, Bridges TM, Blobaum AL, Boutaud O, Daniels JS, Kates MJ, Castelhano A, Rook JM, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Discovery of VU0467319: an M Positive Allosteric Modulator Candidate That Advanced into Clinical Trials ACS chemical neuroscience. 2024 Dec 11; 16 (1) 95-107

2023

Lei X, Hofmann CS, Rodriguez AL, Niswender CM, Differential Activity of Orthosteric Agonists and Allosteric Modulators at Metabotropic Glutamate Receptor 7 Molecular pharmacology. 2023 Apr 27; 104 (1) 17-27
Qi A, Kling HE, Billard N, Rodriguez AL, Peng L, Dickerson JW, Engers JL, Bender AM, Moehle MS, Lindsley CW, Rook JM, Niswender CM, Development of a Selective and High Affinity Radioligand, [H]VU6013720, for the M Muscarinic Receptor Molecular pharmacology. 2023 Aug 18; 104 (5) 195-202
Dogra S, Aguayo C, Xiang Z, Putnam J, Smith J, Johnston C, Foster DJ, Lindsley CW, Niswender CM, Conn PJ, Activation of Metabotropic Glutamate Receptor 3 Modulates Thalamo-accumbal Transmission and Rescues Schizophrenia-Like Physiological and Behavioral Deficits Biological psychiatry. 2023 Dec 05; 96 (3) 230-242

2022

Joffe ME, Maksymetz J, Luschinger JR, Dogra S, Ferranti AS, Luessen DJ, Gallinger IM, Xiang Z, Branthwaite H, Melugin PR, Williford KM, Centanni SW, Shields BC, Lindsley CW, Calipari ES, Siciliano CA, Niswender CM, Tadross MR, Winder DG, Conn PJ, Acute restraint stress redirects prefrontal cortex circuit function through mGlu receptor plasticity on somatostatin-expressing interneurons Neuron. 2022 Jan 18; 110 (6) 1068-1083.e5
Vermudez SAD, Buch A, Weiss K, Gogliotti RG, Niswender CM, Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome Neuropharmacology. 2022 Mar 03; 209 109022
Garrison AT, Orsi DL, Capstick RA, Whomble D, Li J, Carter TR, Felts AS, Vinson PN, Rodriguez AL, Han A, Hajari K, Cho HP, Teal LB, Ragland MG, Ghamari-Langroudi M, Bubser M, Chang S, Schnetz-Boutaud NC, Boutaud O, Blobaum AL, Foster DJ, Niswender CM, Conn PJ, Lindsley CW, Jones CK, Han C, Development of : A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder Journal of medicinal chemistry. 2022 Apr 13; 65 (8) 6273-6286
Luessen DJ, Gallinger IM, Ferranti AS, Foster DJ, Melancon BJ, Lindsley CW, Niswender CM, Conn PJ, mGlu-mediated restoration of prefrontal cortex inhibitory signaling reverses social and cognitive deficits in an NMDA hypofunction model in mice Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2022 May 28; 47 (10) 1826-1835
Smith M, Arthur B, Cikowski J, Holt C, Gonzalez S, Fisher NM, Vermudez SAD, Lindsley CW, Niswender CM, Gogliotti RG, Clinical and Preclinical Evidence for M Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022 Jun 07; 19 (4) 1340-1352
Cikowski J, Holt C, Arthur B, Smith M, Gonzalez S, Lindsley CW, Niswender CM, Gogliotti RG, Optimized Administration of the M PAM VU0467154 Demonstrates Broad Efficacy, but Limited Effective Concentrations in Mice ACS chemical neuroscience. 2022 Jun 07; 13 (13) 1891-1901
Lin X, Fisher NM, Dogra S, Senter RK, Reed CW, Kalbfleisch JJ, Lindsley CW, Asher WB, Xiang Z, Niswender CM, Javitch JA, Differential activity of mGlu allosteric modulators provides evidence for mGlu heterodimers at hippocampal Schaffer collateral-CA1 synapses The Journal of biological chemistry. 2022 Sep 05; 298 (10) 102458
Capstick RA, Whomble D, Orsi DL, Felts AS, Rodriguez AL, Vinson PN, Chang S, Blobaum AL, Niswender CM, Conn PJ, Jones CK, Lindsley CW, Han C, Discovery of a potent M antagonist with improved clearance profile. Part 1: Piperidine amide-based antagonists Bioorganic & medicinal chemistry letters. 2022 Sep 14; 76 128988
Orsi DL, Felts AS, Rodriguez AL, Vinson PN, Cho HP, Chang S, Blobaum AL, Niswender CM, Conn PJ, Jones CK, Lindsley CW, Han C, Discovery of a potent M antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonists Bioorganic & medicinal chemistry letters. 2022 Oct 10; 78 129021

2021

Bender AM, Carter TR, Spock M, Rodriguez AL, Dickerson JW, Rook JM, Chang S, Qi A, Presley CC, Engers DW, Harp JM, Bridges TM, Niswender CM, Conn PJ, Lindsley CW, Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M muscarinic acetylcholine receptor Bioorganic & medicinal chemistry letters. 2021 Nov 24; 56 128479
Hofmann CS, Carrington SJ, Keller AN, Gregory KJ, Niswender CM, Regulation and Functional Consequences of mGlu RNA Editing RNA (New York, N.Y.). 2021 Jul 8;
Joffe ME, Santiago CI, Vermudez SAD, Fisher NM, Dogra S, Niswender CM, Jeffrey Conn P, Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu) impairs postsynaptic plasticity and modulates affective behaviors Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2021 May 25;
Vermudez SAD, Gogliotti RG, Arthur B, Buch A, Morales C, Moxley Y, Rajpal H, Conn PJ, Niswender CM, Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model Genes, brain, and behavior. 2021 May 18; e12752
Xiang Z, Lv X, Lin X, O'Brien DE, Altman MK, Lindsley CW, Javitch JA, Niswender CM, Conn PJ, Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu/mGlu receptor heterodimers Science signaling. 2021 Apr 6; 14 (677)
Dogra S, Stansley BJ, Xiang Z, Qian W, Gogliotti RG, Nicoletti F, Lindsley CW, Niswender CM, Joffe ME, Conn PJ, Activating mGlu Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus Biological psychiatry. 2021 Mar 6;
Kent CN, Fulton MG, Stillwell KJ, Dickerson JW, Loch MT, Rodriguez AL, Blobaum AL, Boutaud O, Rook JL, Niswender CM, Jeffrey Conn P, Lindsley CW, Discovery and optimization of a novel CNS penetrant series of mGlu PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model Bioorganic & medicinal chemistry letters. 2021 Feb 5; 127838
Fisher NM, AlHashim A, Buch AB, Badivuku H, Samman MM, Weiss KM, Cestero GI, Does MD, Rook JM, Lindsley CW, Conn PJ, Gogliotti RG, Niswender CM, A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypes JCI insight. 2021 Jan 21;

2020

Davis DC, Bungard JD, Chang S, Rodriguez AL, Blobaum AL, Boutaud O, Melancon BJ, Niswender CM, Jeffrey Conn P, Lindsley CW, Lead optimization of the VU0486321 series of mGlu PAMs. Part 4: SAR reveals positive cooperativity across multiple mGlu receptor subtypes leading to subtype unselective PAMs Bioorganic & medicinal chemistry letters. 2020 Nov 27; 32 127724
Kalbfleisch JJ, Reed CW, Park C, Spearing PK, Quitalig MC, Jenkins MT, Rodriguez AL, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW, Synthesis and SAR of a series of mGlu NAMs based on an ethyl-8-methoxy-4-(4-phenylpiperazin-1-yl)quinoline carboxylate core Bioorganic & medicinal chemistry letters. 2020 Sep 2; 30 (22) 127529
Reed CW, Kalbfleisch JJ, Wong MJ, Washecheck JP, Hunter A, Rodriguez AL, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW, Discovery of VU6027459: A First-in-Class Selective and CNS Penetrant mGlu Positive Allosteric Modulator Tool Compound ACS medicinal chemistry letters. 2020 Aug 20; 11 (9) 1773-1779
Fulton MG, Loch MT, Rodriguez AL, Lin X, Javitch JA, Conn PJ, Niswender CM, Lindsley CW, Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu heterodimeric receptor results in a compound with mGlu homodimer selectivity Bioorganic & medicinal chemistry letters. 2020 Apr 25; 30 (13) 127212
Fisher NM, Gould RW, Gogliotti RG, McDonald AJ, Badivuku H, Chennareddy S, Buch AB, Moore AM, Jenkins MT, Robb WH, Lindsley CW, Jones CK, Conn PJ, Niswender CM, Phenotypic profiling of mGlu knockout mice reveals new implications for neurodevelopmental disorders Genes, brain, and behavior. 2020 Apr 14; 19 (7) e12654

2019

Fulton MG, Loch MT, Cuoco CA, Rodriguez AL, Days E, Vinson PN, Kozek KA, Weaver CD, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW, Challenges in the Discovery and Optimization of mGlu Heterodimer Positive Allosteric Modulators Letters in drug design & discovery. 2019 Dec 16; 16 (12) 1387-1394
Moran SP, Xiang Z, Doyle CA, Maksymetz J, Lv X, Faltin S, Fisher NM, Niswender CM, Rook JM, Lindsley CW, Conn PJ, Biased M receptor-positive allosteric modulators reveal role of phospholipase D in M-dependent rodent cortical plasticity Science signaling. 2019 Dec 3; 12 (610)
Gregory KJ, Bridges TM, Gogliotti RG, Stauffer SR, Noetzel MJ, Jones CK, Lindsley CW, Conn PJ, Niswender CM, In Vitro to in Vivo Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery ACS pharmacology & translational science. 2019 Nov 15; 2 (6) 442-452
Temple KJ, Engers JL, Long MF, Watson KJ, Chang S, Luscombe VB, Jenkins MT, Rodriguez AL, Niswender CM, Bridges TM, Conn PJ, Engers DW, Lindsley CW, Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M positive allosteric modulator (PAM) chemotype Bioorganic & medicinal chemistry letters. 2019 Nov 13; 30 (3) 126812
Temple KJ, Long MF, Engers JL, Watson KJ, Chang S, Luscombe VB, Rodriguez AL, Niswender CM, Bridges TM, Conn PJ, Engers DW, Lindsley CW, Discovery of structurally distinct tricyclic M positive allosteric modulator (PAM) chemotypes Bioorganic & medicinal chemistry letters. 2019 Nov 11; 30 (4) 126811
Presley CC, Perry CK, Childress ES, Mulder MJ, Luscombe VB, Rodriguez AL, Niswender CM, Conn PJ, Lindsley CW, Evaluation of Synthetic Cytochrome P-Mimetic Metalloporphyrins To Facilitate “Biomimetic” Biotransformation of a Series of mGlu Allosteric Ligands ACS omega. 2019 Jul 26; 4 (7) 12782-12789
Chopko TC, Han C, Gregro AR, Engers DW, Felts AS, Poslusney MS, Bollinger KA, Morrison RD, Bubser M, Lamsal A, Luscombe VB, Cho HP, Schnetz-Boutaud NC, Rodriguez AL, Chang S, Daniels JS, Stec DF, Niswender CM, Jones CK, Wood MR, Wood MW, Duggan ME, Brandon NJ, Conn PJ, Bridges TM, Lindsley CW, Melancon BJ, SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M PAMs Bioorganic & medicinal chemistry letters. 2019 Jun 20; 29 (16) 2224-2228
Xiang Z, Lv X, Maksymetz J, Stansley BJ, Ghoshal A, Gogliotti RG, Niswender CM, Lindsley CW, Conn PJ, mGlu Positive Allosteric Modulators Facilitate Long-Term Potentiation via Disinhibition Mediated by mGlu-Endocannabinoid Signaling ACS pharmacology & translational science. 2019 May 15; 2 (3) 198-209
Gogliotti RG, Niswender CM, A Coordinated Attack: Rett Syndrome Therapeutic Development Trends in pharmacological sciences. 2019 Apr 1; 40 (4) 233-236
Reed CW, Yohn SE, Washecheck JP, Roenfanz HF, Quitalig MC, Luscombe VB, Jenkins MT, Rodriguez AL, Engers DW, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW, Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962) Journal of medicinal chemistry. 2019 Jan 17; 62 (3) 1690-1695

2018

Poslusney MS, Salovich JM, Wood MR, Melancon BJ, Bollinger KA, Luscombe VB, Rodriguez AL, Engers DW, Bridges TM, Niswender CM, Conn PJ, Lindsley CW, Novel M positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands Bioorganic & medicinal chemistry letters. 2018 Dec 18; 29 (3) 362-366
Fisher NM, Seto M, Lindsley CW, Niswender CM, Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders Frontiers in molecular neuroscience. 2018 Dec 14; 11 444
Felts AS, Bollinger KA, Brassard CJ, Rodriguez AL, Morrison RD, Scott Daniels J, Blobaum AL, Niswender CM, Jones CK, Conn PJ, Emmitte KA, Lindsley CW, Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5 Bioorganic & medicinal chemistry letters. 2018 Nov 10; 29 (1) 47-50
Fisher NM, Seto M, Lindsley CW, Niswender CM, Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders Frontiers in molecular neuroscience. 2018 Oct 23; 11 387
Marks CR, Shonesy BC, Wang X, Stephenson JR, Niswender CM, Colbran RJ, Activated CaMKII Binds to the mGlu Metabotropic Glutamate Receptor and Modulates Calcium Mobilization Molecular pharmacology. 2018 Oct 3; 94 (6) 1352-1362
Engers JL, Childress ES, Long MF, Capstick RA, Luscombe VB, Cho HP, Dickerson JW, Rook JM, Blobaum AL, Niswender CM, Engers DW, Conn PJ, Lindsley CW, VU6007477, a Novel M PAM Based on a Pyrrolo[2,3-]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events ACS medicinal chemistry letters. 2018 Sep 4; 9 (9) 917-922
Engers JL, Bender AM, Kalbfleisch JJ, Cho HP, Lingenfelter KS, Luscombe VB, Han C, Melancon BJ, Blobaum AL, Dickerson JW, Rook JM, Niswender CM, Emmitte KA, Conn PJ, Lindsley CW, Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M Positive Allosteric Modulators ACS chemical neuroscience. 2018 Aug 9; 10 (3) 1035-1042
Bertron JL, Cho HP, Garcia-Barrantes PM, Panarese JD, Salovich JM, Nance KD, Engers DW, Rook JM, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW, The discovery of VU0486846: steep SAR from a series of M PAMs based on a novel benzomorpholine core Bioorganic & medicinal chemistry letters. 2018 May 5; 28 (12) 2175-2179
Moran SP, Cho HP, Maksymetz J, Remke DH, Hanson RM, Niswender CM, Lindsley CW, Rook JM, Conn PJ, PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems ACS chemical neuroscience. 2018 Apr 25; 9 (9) 2218-2224
Felts AS, Rodriguez AL, Morrison RD, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA, Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5 Bioorganic & medicinal chemistry letters. 2018 Apr 22; 28 (10) 1679-1685
O'Brien DE, Shaw DM, Cho HP, Cross AJ, Wesolowski SS, Felts AS, Bergare J, Elmore CS, Lindsley CW, Niswender CM, Conn PJ, Differential Pharmacology and Binding of mGlu Receptor Allosteric Modulators Molecular pharmacology. 2018 Mar 15; 93 (5) 526-540
Moran SP, Dickerson JW, Cho HP, Xiang Z, Maksymetz J, Remke DH, Lv X, Doyle CA, Rajan DH, Niswender CM, Engers DW, Lindsley CW, Rook JM, Conn PJ, M-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2018 Mar 14; 43 (8) 1763-1771

2017

Stansley BJ, Fisher NM, Gogliotti RG, Lindsley CW, Conn PJ, Niswender CM, Contextual Fear Extinction Induces Hippocampal Metaplasticity Mediated by Metabotropic Glutamate Receptor 5 Cerebral cortex (New York, N.Y. : 1991). 2017 Nov 9; 28 (12) 4291-4304
Reed CW, McGowan KM, Spearing PK, Stansley BJ, Roenfanz HF, Engers DW, Rodriguez AL, Engelberg EM, Luscombe VB, Loch MT, Remke DH, Rook JM, Blobaum AL, Conn PJ, Niswender CM, Lindsley CW, VU6010608, a Novel mGlu NAM from a Series of -(2-(1-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides ACS medicinal chemistry letters. 2017 Nov 8; 8 (12) 1326-1330

2016

Lindsley CW, Emmitte KA, Hopkins CR, Bridges TM, Gregory KJ, Niswender CM, Conn PJ, Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors Chemical reviews. 2016 Feb 16; 116 (11) 6707-41

2014

Han C, Chatterjee A, Noetzel MJ, Panarese JD, Smith E, Chase P, Hodder P, Niswender C, Conn PJ, Lindsley CW, Stauffer SR, Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators Bioorganic & medicinal chemistry letters. 2014 Nov 18; 25 (2) 384-8
Conn PJ, Lindsley CW, Meiler J, Niswender CM, Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders Nature reviews. Drug discovery. 2014 Sep 3; 13 (9) 692-708
Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, Cherezov V, Conn PJ, Stevens RC, Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator Science (New York, N.Y.). 2014 Mar 6; 344 (6179) 58-64

2013

Manka JT, Rodriguez AL, Morrison RD, Venable DF, Cho HP, Blobaum AL, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA, Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1 Bioorganic & medicinal chemistry letters. 2013 Jul 23; 23 (18) 5091-6
Klein MT, Vinson PN, Niswender CM, Approaches for probing allosteric interactions at 7 transmembrane spanning receptors Progress in molecular biology and translational science. 2013 Jun 15; 115 1-59

2006

Conn PJ, Niswender CM, mGluR7’s lucky number Proceedings of the National Academy of Sciences of the United States of America. 2006 Jan 3; 103 (2) 251-2